China Recombinant Protein Therapeutics Cdmo Market Size & Outlook
Related Markets
China recombinant protein therapeutics cdmo market highlights
- The China recombinant protein therapeutics cdmo market generated a revenue of USD 1,126.1 million in 2023 and is expected to reach USD 2,968.6 million by 2030.
- The China market is expected to grow at a CAGR of 14.9% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
Recombinant protein therapeutics cdmo market data book summary
| Market revenue in 2023 | USD 1,126.1 million |
| Market revenue in 2030 | USD 2,968.6 million |
| Growth rate | 14.9% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, China accounted for 5.4% of the global recombinant protein therapeutics cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan recombinant protein therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 2,968.6 million by 2030.
Interferons was the largest segment with a revenue share of 21.47% in 2023. Horizon Databook has segmented the China recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
In recent years, China has been one of the biggest attractions for the recombinant protein therapeutics CDMO market owing to the increasing number of recombinant protein therapeutics approvals due to their potential to become blockbuster drugs for treating a range of diseases, including cancer, infectious diseases, metabolic diseases, and hematological diseases. Some of the other factors contributing to market growth are rising investments, growing adoption of R&D standards, and robust demand for CDMO.
In addition, the country has witnessed growth in the demand for recombinant proteins in various disease studies. The constant innovation for recombinant protein therapeutics in China is expected to contribute to the country’s market growth. For instance, in December 2022, Innoforce announced that it commenced GMP manufacturing at its new site in China.
The new facility will offer process development & manufacturing services for the global supply of RNA, viral vectors, plasmid DNA, and cell therapeutics across research, clinical, & commercial stages. All these factors are anticipated to positively influence the recombinant protein CDMO market in China.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Enzene Biosciences | View profile | 251-500 | Pune, Maharashtra, India, Asia | http://www.enzene.com/ |
| Biovian | View profile | 101-250 | Turku, Western Finland, Finland, Europe | http://www.biovian.com |
| HALIX | View profile | 11-50 | Leiden, Zuid-Holland, The Netherlands, Europe | https://www.halix.nl |
| Richter-Helm | View profile | 251-500 | Hamburg, Hamburg, Germany, Europe | http://www.richter-helm.eu |
| Batavia Biosciences | View profile | 101-250 | Leiden, Zuid-Holland, The Netherlands, Europe | http://www.bataviabiosciences.com/ |
| Curia | View profile | 1001-5000 | Albany, New York, United States, North America | https://curiaglobal.com |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| WuXi Biologics (Cayman) Inc | View profile | 12740 | No. 108, Meiliang Road, Mashan Binhu District, Wuxi, China, People's Republic of, 214092 | https://www.wuxibiologics.com |
| FUJIFILM Holdings Corp | View profile | 83784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | http://www.fujifilmholdings.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
China recombinant protein therapeutics cdmo market size, by source, 2018-2030 (US$M)
China Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
